Length of Ischemic Time Is Critical for Accurate Determination of Homologous Recombination Capacity by Immunofluorescence Staining in Ovarian Cancer Formalin-Fixed Paraffin-Embedded Samples
In brief
Delayed tissue processing lowers ovarian cancer HR scores and creates false deficiency calls
In ovarian high-grade serous cancer samples, prolonged time before processing reduced the RAD51 signal and caused some tumors to be misclassified as homologous recombination deficient. Other tested handling conditions had no significant effect, and results were consistent across tumor regions. Functional HR testing may be unreliable when archival sample handling times are unknown, which could affect patient selection for PARP inhibitors.
- Journal
- Archives of pathology & laboratory medicine (Q1)
- Published
- 17 November 2026
- Study design
- Prospective / inception cohort
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Ezgi Karagöz, Sanna Pikkusaari, Minna R Eriksson, Srividhya Sundaresan, Matilda Salko, Jaana Oikkonen, et al.
- PMID
- 43042964
- DOI
- 10.5858/arpa.2025-0479-OA
Why clinicians should know about it
- Picked for Pathology and Forensic Medicine (paper of the day, 19 November 2026): Preanalytic ischemia effects on functional HR immunofluorescence
Abstract
CONTEXT.—: Tubo-ovarian high-grade serous carcinomas (HGSC) that are deficient in homologous recombination (HR) are more sensitive to poly ADP-ribose polymerase (PARP) inhibitors than their HR-proficient counterparts. To target PARP inhibitors to the right patients, HR status must be accurately determined. Functional HR (fHR) assays, which assess HR status by quantifying RAD51, are promising approaches for identifying HR-deficient cases. However, these tests have yet to be optimized for pre-analytical variables and tissue properties that may impact RAD51 quantification. OBJECTIVE.—: To establish how typical pre-analytical variables (ischemic time, formalin fixation, and ethanol storage) and tissue-level necrosis and hypoxia affect read-outs of fHR capacity, with systematic evaluation of prolonged ischemic time. Additionally, biological (intra-tumor) variation in fHR measurements was assessed. DESIGN.—: The immunofluorescence-based fHR assay was performed on a retrospective and a prospectively collected cohort of formalin-fixed paraffin-embedded HGSC specimens with varying pre-analytical and tissue-level conditions. Intra-tumor variation in fHR capacity was assessed in multiple tumor areas and independent tumor pieces. RESULTS.—: Prolonged ischemic time led to a substantial reduction in nuclear RAD51 signal, resulting in lower fHR scores and false fHR deficiency calls. The other examined variables did not significantly impact fHR scores. Intra-tumor variation in fHR scores was low, and the fHR category, when determined from different regions of the same tumor, remained unchanged. CONCLUSIONS.—: Prolonged ischemic time adversely affects fHR assay performance, highlighting the importance of monitoring and documenting sample handling processes, particularly in HGSC, and warrants caution when interpreting fHR results from archival tumor material for which such information is unavailable.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.